ProCE Banner Activity

Hepatitis Delta in Focus: Episode 4 of Answering the Questions on Screening, Diagnosis, and Treatment

Podcast Episodes

In this podcast episode, listen to expert faculty perspectives on HDV management, including screening, staging liver disease, approach to treatment—such as whom to treat and for how long—and considerations for combination therapy.

Released: June 22, 2023

Share

Faculty

Tarik Asselah

Tarik Asselah, MD, PhD

Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris-Cité & INSERM 
Clichy, France

Ira Jacobson

Ira Jacobson, MD

Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Provided by

Provided by Clinical Care Options LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and Janssen Therapeutics Division of Janssen Products 

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Disclosure

Primary Author

Tarik Asselah, MD, PhD

Professor of Medicine
Department of Hepatology
Hôpital Beaujon
Université de Paris-Cité & INSERM 
Clichy, France

Tarik Asselah, MD, PhD: consultant/advisor/speaker: Antios, Eiger, Enyo, Janssen, Gilead, GlaxoSmithKline, Roche, Vir Biotechnology.

Ira Jacobson, MD

Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Ira Jacobson, MD: consultant: Aligos, Arbutus, Gilead Sciences, Intercept, Merck, Roche; researcher: Assembly, Cymabay, Eiger, Galectin, Genfit, Genkyotex, GlaxoSmithKline, Intercept, Janssen, Lilly, Mirum, Novo Nordisk; data monitoring committee: Altimmune, GlaxoSmithKline, Takeda.